|
May 7
|
Expediting parallel drug approval pathways is challenging, but rewarding
|
|
May 7
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
|
|
May 7
|
EC approves AstraZeneca’s Calquence combo to treat MCL
|
|
May 7
|
Tempus AI Inc (TEM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
|
|
May 6
|
AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing
|
|
May 6
|
AZN or ARGX: Which Is the Better Value Stock Right Now?
|
|
May 6
|
AstraZeneca's (LON:AZN) Earnings Offer More Than Meets The Eye
|
|
Mar 19
|
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
Mar 19
|
AstraZeneca (AZN): Among the Best Diabetes Stocks to Buy According to Billionaires
|
|
Mar 19
|
3 UK Stocks Estimated To Be Trading At Discounts Of Up To 48.5%
|
|
Mar 18
|
Is AstraZeneca (AZN) the Best European Stock to Buy According to Billionaires?
|
|
Mar 18
|
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
|
|
Mar 18
|
Stoke CEO exits; Medicare drug price talks advance
|
|
Mar 18
|
AstraZeneca and Alteogen agree on ALT-B4 platform tech
|
|
Mar 17
|
Sector Update: Health Care Stocks Rise Late Afternoon
|
|
Mar 17
|
European Equities Rise in Monday Trading; AstraZeneca to Acquire EsoBiotec for Up to $1 Billion
|
|
Mar 17
|
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
|
|
Mar 17
|
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
|
|
Mar 17
|
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
|
|
Mar 17
|
Eventful Monday For AstraZeneca - What's Going On?
|